Home » Market News » DirectorsTalk Highlights » Are we becoming more allergic?
Allergy therapeutics plc

Are we becoming more allergic?

According to new figures, the number of people admitted to hospital in Yorkshire with allergic reactions has risen dramatically over the past few years.

The reasons for this are unclear. Are we becoming more allergic? Or are we better at diagnosing allergies now?

Many of my clients suffer from food allergies and intolerances. These range from severe, dramatic, life-threatening reactions such as anaphylactic shock, to more chronic, non-urgent responses such as headaches and skin rashes.

 

Allergy Therapeutics (LON:AGY) is an international commercial biotechnology group focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

 

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.